Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Avoiding patient morbidity: Updated statin drug interactions and risks for patient harm

Finks, Shannon W. PharmD, FCCP, BCPS; Campbell, Jennifer D. PharmD, CDE

doi: 10.1097/01.NPR.0000443232.02852.f8
Feature: PHARMACOLOGY
Buy
SDC

Abstract: Almost 50% of serious adverse events with statin therapy are attributed to unfavorable drug-drug combinations. This article reviews updated FDA warnings on capping the dose of simvastatin, recent package insert labeling changes of particular statins that address combinations with potent cytochrome P450 inhibitors, and current renal dosing recommendations for statins.

Almost 50% of serious adverse events with statin therapy are attributed to unfavorable drug-drug combinations. This article reviews updated FDA warnings on capping the dose of simvastatin, recent package insert labeling changes on particular statins that address combinations with potent cytochrome P450 inhibitors, and current renal dosing recommendations for statins.

Shannon W. Finks is an associate professor at the University of Tennessee, College of Pharmacy, Memphis, Tenn. Jennifer D. Campbell is a Clinical Pharmacist of Ambulatory Care at Regional Medical Center, Memphis, Tenn.

The authors have disclosed that they have no financial relationships related to this article.

© 2014 Lippincott Williams & Wilkins